LTZ Therapeutics
Latest round
- Series A
Last raised
- Apr 2025
Total raised
- $60M
Investors
- 9
About LTZ Therapeutics
, trading under the name LTZ Therapeutics, provides innovative immunotherapy drugs for the healthcare sector. It has established strategic transactions with global pharmaceutical companies such as Eli Lilly and GSK. The company focuses on the research and development of new immunotherapies, and its main products are based on the Myeloid Engager Platform. The product pipeline includes LTZ-301, LTZ-232, and LTZ-233. LTZ-301 is a new myeloid adapter bispecific antibody that can be used to treat relapsed or refractory non-Hodgkin's lymphoma. LTZ-232 and LTZ-233 are mainly targeted at solid tumors. The original new drugs developed by the company are used in the fields of tumors and autoimmune diseases. The company generates revenue through the research and development of original new drugs in the oncology and autoimmune fields, alongside strategic collaborations and licensing transactions with multinational pharmaceutical corporations.
Who invested in LTZ Therapeutics
9 investors across 2 rounds
See all investors in LTZ Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about LTZ Therapeutics
Who invested in LTZ Therapeutics?
LTZ Therapeutics has 9 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has LTZ Therapeutics raised?
LTZ Therapeutics has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did LTZ Therapeutics last raise money?
LTZ Therapeutics's most recent round on record is a Series A, in Apr 2025.
What does LTZ Therapeutics do?
, trading under the name LTZ Therapeutics, provides innovative immunotherapy drugs for the healthcare sector.
Where is LTZ Therapeutics headquartered?
LTZ Therapeutics is headquartered in Redwood City, US.
Which VCs invest in companies like LTZ Therapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at LTZ Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like LTZ Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.